Introduction
The ability of hematopoietic growth factors (HGF) to mobilize progenitors into the peripheral blood (PB) either with or without chemotherapy has now been well established. Clinical studies show that mobilized PB progenitor cells infused after myeloablative therapy cause a rapid and sustained recovery of the blood cell counts. 1, 2 However, despite the increasing knowledge of progenitor/stroma interaction, the mechanisms of progenitor cell mobilization remain undefined. In addition to promoting survival, proliferation and development of hematopoietic progenitors, HGF also regulate adhesive interactions between progenitor cells and the BM microenvironment by modifying the functional states of the ␤1 integrins very late antigen 4 (VLA-4) and VLA-5, that are expressed on hematopoietic progenitor cells. 3 Administration of monoclonal antibodies against VLA-4 in primates induces mobilization of progenitor cells into the peripheral blood. 4 An important difference between bone marrow (BM) and HGF-mobilized PB progenitors is the higher number of noncycling cells [5] [6] [7] [8] [9] [10] and rhodamine dull cells 5 present in PB. These findings are of interest, because cell cycle status may have impact on conditions for ex vivo expansion, retrovirusmediated gene transfer, in vitro cell treatment (such as purging) and engraftment of transplanted tissues. In normal BM 90% of the pluripotent stem cell population has been shown to be non-cycling 11 and at least part of these cells are rhodamine dull. [12] [13] [14] Therefore it has been hypothesized that during mobilization a selective release of primitive, non-cycling, rhodamine dull stem cells occurs. Clinical observations indicate that mobilized PB progenitors contain stem cells, as their administration after high-dose therapy gives long-term repopulation. Indeed, primitive progenitors have also been observed in mobilized PB, 15-17 but their frequency is not higher in PBPC harvests than BM harvests if LTC-IC assays are used. An alternative explanation might be that progenitor cells, independent of their differentiation status, lose their cycle status after mobilization due to loss of contact with the BM microenvironment. In this study, we looked at the cell cycle status and rhodamine content in CD34
+ cells from normal BM, mobilized PB and BM aspirated during mobilization, using flow cytometric determination of the S-phase DNA with the DNA-specific dye propidium iodide (PI) and a rhodamine 123 efflux assay. To investigate whether the S-phase status of CD34 + cells in BM, mobilized PB and BM during mobilization was correlated with the primitive or more mature status of the progenitor, we measured the cycling status by propidium iodine staining in subfractions on the basis of lineage-associated markers and cloning in single cell assay.
Our findings indicate that during mobilization the progenitors in the PB are a selection of more primitive progenitors, defined by immunophenotype (CD34
dim ) and growth pattern in single cell colony-forming assay. Almost all progenitors, both primitive and more differentiated are in G 0 /G 1 . A significantly higher proportion of the progenitors are rhodamine dull, which correlated with their non-cycle status.
Materials and methods

Cells
PBPC were collected from patients with multiple myeloma (stage III, according to Durie and Salmon, all patients previously treated) using the Fenwal CS3000 plus blood processor (program 1 mod; Baxter, Deerfield, IL, USA). 18 The mobilization regimen consisted of high-dose cyclophosphamide (7 g/m 2 , i.v.) on day 0 followed by HGFs. Three patients received rhuGM-CSF (5 g/kg/day i.v./s.c.), two patients rhuG-CSF (5 g/kg/day s.c.) and 1 patient placebo s.c. from day 1 until completion of leukapheresis harvests. Leukaphereses were performed on days 14-21 (median day 15) after infusion of cyclophosphamide with a median of four procedures (range 4-6) per patient.
After informed consent in the same six myeloma patients 5 ml BM was also aspirated from the sternum prior to one of the leukapheresis procedures, designated as 'BM during mobilization'.
BM aspirates for control experiments were taken from donors for allogeneic bone marrow transplantation. After informed consent, 50-100 ml bone marrow was aspirated from the iliac crest under general anaesthesia after collection of bone marrow for transplantation.
After washing the BM/PB cells and removal of fat and the excess of thrombocytes, mononuclear cell were isolated by Ficoll (Sigma, St Louis, MO, USA) 1.077 g/mol density centrifugation.
CD34 selection
Mononuclear cells were washed and mixed with '561' CD34 antibody covalently bound to paramagnetic M450 beads (Dynal, Oslo, Norway) at a cell to bead ratio of 1:2 in 1 ml glucose phosphate buffer with 1% bovine serum albumin (BSA) (buffer). The cells were incubated according to the manufacturer's protocol. The cells were enumerated using a Coulter counter (Coulter, Hialeah, FL, USA). Part of the cells were labelled for immunophenotyping and culturing in single cell assay and part of the cells were cryopreserved (Kryo 10; PlanerBiomed, Sunbury, UK) in 2 ml freezing tubes in the presence of 10% DMSO and stored at −198°C for future experiments. The purity of CD34-selected PB and BM progenitor cells was 95% (87-99%). The depleted fraction was almost devoid of CD34 + cells.
Thawing and labelling of BM/PB CD34-selected cells and transferrin 0.3 mg/ml (Sigma). The following recombinant growth factors were added: IL-3 (50 ng/ml) (Sandoz Pharma, Basel, Switzerland), G-CSF (20 ng/ml) (Amgen, Thousand Oaks, CA, USA), GM-CSF (20 ng/ml) (Sandoz, Pharma), erythropoietin (1.5 U/ml) (Eprex; Cilag, Zug, Switzerland) and SCF (25 ng/ml, a gift from Amgen). The plates were placed in an incubator at 37°C, 5% CO 2 , in a fully humidified atmosphere.
Evaluation of growth and differentiation in the single wells
The cells in each individual well were counted under an inverted microscope. One day after single cell sorting cells were found in about 90% of the wells. Counting was started on day 5 after culturing and repeated weekly until the colonies were fully differentiated, stopped growing or became pycnotic. The size of large colonies (Ͼ 1000 cells) was estimated. Apart from the number of cells the configuration of the cells while differentiated was noted as granulocytic, monocytic, erythroid and combinations of these. The morphology of colonies was checked on May-Grü nwald Giemsa-stained cytospin slides. Plating efficiencies were defined as the percentage of wells with colonies consisting of more than 50 cells, more than 500 cells or more than 5000 cells after 3 weeks of culturing.
Rhodamine efflux assay
Rhodamine (Rh123; Sigma) was dissolved in distilled water (dH 2 O) and stored as a sterile stock solution (10 g/ml). Rhodamine staining was performed according to the method described by Bertoncello et al. 14 Briefly, CD34 + cells were incubated (2 × 10 5 cells/ml) in Iscove's medium with a final rhodamine concentration of 0.1 g/ml, for 60 min, at 37°C. After centrifugation, cells from normal BM and mobilized PB cells of patients were resuspended in dye-free Iscove's medium and incubated at 37°C to allow the efflux of the fluorochrome. A time course of 2 h efflux was used. The rhodamine 123-labelled cells were incubated with PE-conjugated HPCA-2. Analysis was performed on a Coulter Epics Elite Hypotonic DNA staining and flow cytometry CD34
+ progenitors from steady-state BM, mobilized PB and BM during mobilization were assessed for their content of cells in S/G 2 M-phases. Steady-state BM was obtained from four myeloma patients before start of their mobilization regimen and in seven donors for allogeneic transplantation. Mobilized PB was obtained from seven myeloma patients and four patients with other malignant disorders. BM during mobilization was obtained from six myeloma patients during the apheresis procedure. CD34
+ cells were either obtained by immunomagnetic bead selection or FACS sorting after CD34-Cy5 labelling. S/G 2 M was assessed using the method, previously described by Brons et al. 19 
Statistical analysis
Statistical analysis was carried out by Wilcoxon test for paired and unpaired data, when appropriate.
Results
Cytofluorometric analysis of mobilized PB and bone marrow CD34
+ cells
The percentage of CD34 + cells expressing CD13 + in mobilized PB was significantly higher than in BM (median 70% vs 53%) (P = 0.006) and the percentage of CD19
+ cells was significantly lower in PB than in BM (median 5% and 23%) (P = 0.001) ( bright fraction showed similar plating efficiency in BM and PB. This fraction was markedly enriched for erythroid colonies (CFU-E). The CD13 − /33 dim fraction showed a similar plating efficiency: 26% and 31%, and was also enriched for erythroid colonies. The CD13 − /33 dim fraction had a relatively low plating efficiency both in BM and PB (17% and 23%) and contained more mature erythroid colonies (CFU-E).
Interestingly, the patient who only received chemotherapy without the adjunct of haematopoietic growth factors, had a relatively high content of mixed colonies in CD34-selected progenitors (24%) as compared to the other five patients who all received either G-or GM-CSF (mean 11%).
Rhodamine assay
The intensity of Rh123 staining of CD34 + cells was expressed as bright, intermediate or low. In PBPC harvests all five CD34 samples tested contained a significantly larger fraction of Rh123 dull staining cells (mean 54%, range 45-61%) compared to six samples of normal BM (mean 22%, range 20-26%) (P = 0.014) (Figure 1 ).
Propidium iodide assay
The number of beads selected or FACS sorted CD34 + cells in the S/G 2 M-phase of the cell cycle was significantly lower in mobilized PB (n = 11) than in normal BM (n = 11): 2.1% vs 18% (P = 0.002). In steady-state BM the median fraction of CD34 + cells engaged in the S/G 2 M-phases of the cell cycle was similar to that in BM, aspirated at the same time as the apheresis procedures (n = 7); 18% and 16% (P = 0.34) (Figure 2 + /33 bright fraction: 3% and 2% (P = 0.03) (n = 10).
Discussion
The very low proliferate state of mobilized PB CD34 + cells reported by other investigators [5] [6] [7] [8] [9] [10] was confirmed in this study. In addition, we showed that during the mobilization period the fraction of BM progenitors in proliferation was comparable to the proliferating fraction in steady-state BM. Furthermore, comparison of BM and mobilized PB progenitors showed a difference in rhodamine retention. The fraction of rhodamine dull cells, was much higher in the PB (54%) than in the BM (22%) CD34
+ cells (P = 0.014). In normal BM rhodamine dull cells are considered to be more primitive progenitors, suggesting also that the mobilized PB CD34
+ cells are primitive progenitors. Analysis of the state of differentiation based on immunophenotype showed that mobilized PB contained few lymphoid precursors (CD34 + , CD19 + ) in contrast to the BM (5% vs 23%). The lower proportion of CD34
+ expressing the B cell-associated molecule CD19 in mobilized PB compared to BM has also been reported by others 5, 20, 21 as well as the higher expression of single myeloid antigens such as CD13. 5, 20 Comparison of the non-lymphoid CD34 + cells in BM and PB revealed more differentiated myeloid progenitors (CD13
bright ) in BM than in mobilized PB (51% vs 36%).
Cloning of the progenitors in single cell assay showed that within the CD13 bright fraction of three different donors (P Ͻ 0.0001). Analysis of the cell cycle status within these fractions showed that the more differentiated myeloid progenitors contained a higher percentage of cells in the S/G 2 M phase than the more primitive progenitors. This was true for both PB and BM, although, as mentioned before, the absolute number of cells in S/G 2 M phase was much lower in the mobilized PB CD34
+ cells. From our data it can be concluded that mobilization of CD34 cells into the peripheral blood is not a random 'spillover' process. The progenitors are immunophenotypically less differentiated (more primitive mixed colonies and HPP-CFC) and fewer lymphoid precursors are mobilized into the PB. Progenitors that appear in the PB, both primitive and more
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Figure 1
Representative example of rhodamine content of CD34 + cells after 2 h efflux in dye-free medium. Upper panel, two normal BM samples; lower panel, two mobilized peripheral blood samples. differentiated are mainly non-cycling, which may be due to selective release from the BM. An alternative explanation is that loss of contact with the BM stromal cells occurs, which is necessary for proliferation induction, hypothesizing that interactions with the stroma through adhesion molecules, growth factors and chemokines are necessary for proliferation.
Reports on the relative content of mature vs more primitive progenitors in mobilized PB vs BM are inconclusive. Several authors 20, 21, 23, 24 have observed differences between BM and PB CD34
+ progenitors in terms of a predominance of expression of myeloid antigens in CD34-positive PB progenitor cells over those in BM after administration of granulocyte colony-stimulating factor 23, 24 or in steady-state BM. 21 No definite explanation is available at present why few mobilized PBPC are in S phase. The differences in cell cycle between BM and mobilized PB progenitors are of interest, as it might provide more insight in the commonly used term 'mobilization'. It has been proposed that down-modulation of adhesion markers on resting primitive PBPC in the marrow by mobilizing agents may result in their release into the periphery. 29 Our findings indicate that, indeed, more primitive progenitors are present in PB than in BM, characterized by immunophenotype (CD34 12, 30 The difference in mobilized CD34
+ cells from steady-state BM CD34
+ cells in terms of retaining less rhodamine 123 has also been reported by To et al. 5 Therefore, a selective release of a 
Figure 2
Percentage of CD34 + cells in SG 2 /M-phase in mobilized PB, steady-state BM and BM during mobilization. more primitive population is likely. However, our data show that also the mature mobilized PBPC are in a non-cycling phase.
Therefore the peripheral blood microenvironment does not seem to provide adequate support to trigger the proliferation or expansion of progenitor cells, irrespective of their differentiation state. This seems to be confirmed by recent data of Uchida and colleagues 31 who showed the delayed entry into S-phase of mobilized PB CD34 + /Thy-1
+
/Lin
− cells compared to their BM counterparts. Recently, however, Lemoli et al 27 described G-CSF-mobilized PB CD34
+ cells to be ready to progress into S-phase under CSF stimulation. An inhibitory stimulus of the PB microenvironment may also be hypothesized. However, studies by Roberts et al 6 showed, using the tritiated thymidine suicide assay, that the non-cycling state of mobilized PB was not due to inhibitory substances in the blood or to hyporesponsiveness to growth factors.
In conclusion, our findings indicate that more primitive progenitors are present in PB than in BM. Rhodamine dull, noncycling progenitors include cells with a more differentiated phenotype. The low cycling status of mobilized PB CD34 + cells may suggest different adhesive properties of migrating/mobilized stem cells which may require the BM microenvironment for adequate proliferation in vivo.
